Currently Viewing:
Kidney Week 2019
Currently Reading
Time to Focus on Increasing Organs for Patients With ESRD, Azar Says at Kidney Week
November 07, 2019
Dr Danielle Kirkman Explains How Exercise Testing in Patients With CKD Can Improve Care
November 07, 2019
Dr Cynthia Delgado on the Importance of Patient Input in Kidney Disease Care
November 08, 2019
Data From 3 Roxadustat Trials Lead Off Kidney Week Sessions Ahead of Efficacy, Safety News
November 08, 2019
Dr Joseph Vassalotti Presents Findings of AJMC® Study on CKD Intervention
November 08, 2019
Dr Alan Kliger Outlines Major Safety Risks for Patients Receiving Dialysis
November 08, 2019
Researchers Develop Tool to Identify Those at Risk of Future CKD
November 08, 2019
Paul Conway: Respect, Listening Are Keys to Engaging Patients in Kidney Care
November 08, 2019
Pooled Cardiovascular Data on Roxadustat Show No Increased Risk to Patients With CKD
November 08, 2019
Dr Jay Wish Explains Implications of New Roxadustat Data
November 09, 2019
Patients on Dialysis Have More Hospitalizations in Areas With More Black Residents
November 09, 2019
Physicians, Patient Discuss Intentional Nonadherence in Hypertension Therapy
November 10, 2019
Dr Holly Kramer Discusses Components of the Advancing American Kidney Health Initiative
November 11, 2019
Early Warning Signs of CKD Going Unnoticed in Veterans, Especially Those With Hypertension
November 11, 2019
As Kidney Week Ends, Providers Are Urged to Join New Care Models
November 11, 2019
Understanding More About Quality of Life Impact for Patients With CKD, Anemia
November 11, 2019
Dr Tammy Brady Explains Special Considerations in Pediatric Nephrology
December 05, 2019
Dr Danielle Kirkman Discusses the Biological Relationship Between Exercise and Hypertension
December 10, 2019
Dr Joseph Vassalotti on How Risk Stratification Informed a Primary Care CKD Intervention
December 11, 2019
Dr Tammy Brady on the Dangers of Missed, Incorrect Hypertension Diagnoses in Children
December 16, 2019
Dr Joseph Vassalotti Discusses Upstream Interventions Based on CKD Risk Stratification
December 20, 2019
Dr Danielle Kirkman on the Integration of Exercise Into the CKD Care Plan
December 23, 2019
Dr Tammy Brady Describes Efforts to Improve Diagnosis of Hypertension in Children
December 24, 2019
Dr Tammy Brady on Exciting Advances in Pediatric Nephrology
December 30, 2019

Dr Joseph Vassalotti Explains How CKDintercept's Components Can Improve Kidney Care

CKDintercept, the primary care initiative of the National Kidney Foundation, involves multiple strategies aimed at improving the quality of kidney care, explained Joseph Vassalotti, MD, clinical professor at Icahn School of Medicine at Mount Sinai and chief medical officer of the National Kidney Foundation.


CKDintercept, the primary care initiative of the National Kidney Foundation, involves multiple strategies aimed at improving the quality of kidney care, explained Joseph Vassalotti, MD, clinical professor at Icahn School of Medicine at Mount Sinai and chief medical officer of the National Kidney Foundation.

What is CKDintercept and how do you hope it will improve kidney care?

CKDintercept is the National Kidney Foundation’s primary care initiative. It’s a multipronged effort, which includes simplifying the laboratory tests to make it easier for the primary care clinician to order the estimated GFR [glomerular filtration rate] and the urine albumin to creatinine ratio with Kidney Profile that includes those 2 tests. We’re also harmonizing the way the tests are reported, so that the reporting formats and the formulas used to calculate the estimated GFR are harmonized across the laboratories. And we’re partnering with the laboratory societies and clinical laboratory professionals to implement this work together. 

It also includes a quality measure. Unfortunately, we don’t have any quality measures in all of Medicare or Medicaid for chronic kidney disease. Medicare and Medicaid have many quality measures for kidney failure or end-stage renal disease treated with dialysis or transplant, but there’s nothing, so we want to start with the quality measure there. We want to replace the existing medical attention for nephropathy measure that’s in the HEDIS [Healthcare Effectiveness Data and Information Set] program. That’s the commercial insurance acronym for the quality measure program with the simpler quality measure that includes the estimated GFR and the urine albumin to creatinine ratio in the patients with diabetes. 

That should drive the testing for kidney disease. At this point, the average American with diabetes gets an estimated GFR 80% to 90% of the time, depending on which data set you looked at, you look at over a year period, but the urine albumin to creatinine ratio in most of the data sets we’ve looked at only is done about 40% of the time. We want to increase the testing of the population with diabetes at risk for kidney disease with this quality measure. 

Then there is an educational aspect, and really a lot of this will involve working with primary care clinicians and primary care societies to show how that heat map risk stratification, how the lower estimated GFR and the increase in the albuminuria predict risk and how they actually should guide interventions, like the ones that I mentioned before, ACE [angiotensin-converting enzyme] inhibitors and angiotensin receptor blockers, when to refer to a nephrologist, more intensive cardiovascular risk reduction with statin-based therapy, and others. 

The other programs within the CKDintercept include a payment model that we’re working on to innovate care, both in the primary care setting and the nephrology setting, so to incentivize the primary care clinician and the nephrologist for evidence-based interventions which should lead to better outcomes for people living with chronic kidney disease.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up